Merck & Co.: KEYTRUDA and QLEX Generated 50.4% of Second-Quarter Revenue While Subcutaneous Sales Rose to 463 Million Dollars Before the 2028 Patent Cliff

Claims that QLEX categorically secures the franchise “through 2039” are not sufficiently verified. The FDA approved QLEX on September 19, 2025, and the Purple Book records it as a separate 351(a) biologics license with that original approval date. The public Purple Book entry does not establish a blanket 2039 exclusivity date. Formulation, device, enzyme and manufacturing patents may provide protection, but their enforceability, geographic scope and ability to prevent alternative subcutaneous products require patent-by-patent analysis. The valuation below therefore models QLEX through conversion and retained cash flow rather than assuming a guaranteed exclusivity year.

Biosimilar competition is near and concrete. Samsung Bioepis reported that its SB27 studies met key pharmacokinetic and efficacy-equivalence endpoints; Celltrion has been advancing CT-P51, while Amgen, Sandoz and other sponsors have clinical programs. FDA’s 2026 draft policy also sought to reduce portions of the evidence burden for biosimilar development. Exact launch dates will depend on approvals, litigation and settlements, but a scenario in which only one cautious competitor appears well after 2029 is too benign for a conservative valuation.

Qualitatively, Merck is a company in transition. It retains high fundamental quality: deep oncology evidence, global manufacturing, regulatory capability, strong cash generation and a long history of turning clinical science into widely adopted medicines. Its growth quality is more mixed, because half of current sales sit in one family approaching loss of exclusivity. Management has already produced one clear acquisition success under CEO Robert Davis: the $11.5 billion Acceleron purchase brought sotatercept, now WINREVAIR, which was producing quarterly revenue of $588 million less than two and a half years after approval. Prometheus and Verona have also supplied plausible second-wave assets. Cidara and Terns move farther out on the risk curve, where purchase prices are large relative to clinical maturity.

The stock’s history explains its present valuation. Investors re-rated Merck as KEYTRUDA evolved from a 2014 melanoma treatment into the industry’s largest prescription-drug franchise. The rating then contracted when Gardasil weakness in China, 2026 guidance and the post-2028 gap made concentration impossible to ignore. Merck’s 52-week share-price range through August 4, 2026 was approximately $77.58–135.05; at $128, it had recovered most of the decline and had risen roughly 60% over the preceding year. The recovery reflects genuine evidence: QLEX uptake, WINREVAIR growth, pipeline successes and a raised sales outlook. It also means the market no longer offers the severe pessimism visible near the 2025 low.

My independent work reaches a different rating from the May 25, 2026 library report. The earlier report rated Merck Watch at a stale $122.41 reference price. I rate it Hold at the verified August 4 close of $128.00. New facts account for part of the change: QLEX’s Q2 sales substantially exceeded expectations, revenue guidance rose, LIPFENDRA gained approval, TroFuse-005 succeeded, tulisokibart produced positive Phase III ulcerative-colitis data, and the weekly HIV regimen succeeded in Phase III. Different judgment accounts for the rest: I assign more present value to Merck’s launch portfolio and broad oncology platform, while charging the company more explicitly for acquisition capital and for plausible early biosimilar entry. The result is not a simple upward adjustment of the prior ranges; the valuation was rebuilt from explicit post-2028 scenarios.

At the current price, Merck is neither obviously cheap nor priced as a compounder that grows without interruption. The charge-adjusted near-term earnings multiple is modest, but near-term earnings are the asset being depleted. My base present value is about $130 per share, close to the market. The conservative value is about $110, while the optimistic case reaches about $158. A purchase at $128 offers no discount to the conservative case and only a small discount to base value. The 2.7% dividend yield does not compensate for that lack of margin of safety when the 10-year Treasury yielded 4.63% on August 4, 2026.

Company Vertical History, Financial Evolution, and Capital-Market Narrative

Merck’s origin was distribution rather than biotechnology. George Merck founded the U.S. company in New York on January 1, 1891 to distribute fine chemicals. The company published the first Merck Manual in 1899, and George W. Merck’s decision to build an internal research institution changed its identity. The Rahway research laboratory, established in 1933, moved Merck from selling compounds toward discovering medicines; early work included vitamin synthesis, cortisone and support for streptomycin research. That transition created the business model seen today: risking capital on proprietary science, securing regulated exclusivity, manufacturing globally and reinvesting high margins into the next generation.

The U.S. company’s separation from the German Merck enterprise was shaped by the First World War and subsequent trademark arrangements. It became an independent American company and ultimately retained the Merck name in the United States and Canada, while the German company retained it elsewhere. That institutional history is why Merck & Co. markets itself as MSD in most international markets and why careless search results frequently combine two unrelated companies.

Historical databases place Merck’s NYSE listing in 1941. This was not an IPO in the modern prospectus-and-roadshow form, and I could not verify a reliable primary record for an offering price, proceeds or first-day valuation. Those figures should therefore be treated as unavailable rather than reconstructed from unsourced historical databases. What matters more for capital markets is that Merck entered the post-war era as a research-centered public drug company and used public-company capital access to build manufacturing, international distribution and a succession of patent-protected franchises.

Merck’s history divides into five economically distinct stages.

The first stage, from 1891 through the early post-war period, converted a chemical distributor into a research organization. The strategic constraint was scientific capability: distribution scale alone offered limited pricing power, whereas patented medicines could create both social value and attractive economics. The 1927 merger with Powers-Weightman-Rosengarten increased scale, while the Rahway laboratory institutionalized pharmacological research. The lasting asset was a corporate system capable of moving discoveries through development and manufacturing rather than any single product.

From the 1950s through the early 2000s, the second stage made Merck one of the defining research-led pharmaceutical companies. Its franchises spanned vaccines, cardiovascular medicines, infectious disease and primary care. Successful products such as antihypertensives and statins reinforced a model in which large primary-care markets supported extensive salesforces and research budgets. This period established the company’s vaccine capability and physician relationships, but it also exposed the recurring weakness of branded pharmaceuticals: each generation of blockbuster cash flow eventually encounters generic competition.

The third stage was consolidation around the 2009 Schering-Plough merger. Merck agreed to pay $41.1 billion, a 34% premium to Schering-Plough’s prior close, with approximately 44% cash and 56% stock. Schering-Plough shareholders would own roughly 32% of the combined group. The transaction was structured as a reverse merger in which the Schering-Plough legal entity survived under the Merck name, partly preserving contractual rights that might otherwise have been affected by a conventional change of control. Merck sought a broader specialty portfolio, international reach, biologics capacity and $3.5 billion of annual cost savings. The deal genuinely changed the company’s scale and supplied assets and capabilities that supported the later oncology era, although it also illustrated how large pharma often buys breadth after internal franchises mature.

The fourth stage began with KEYTRUDA’s first FDA approval in 2014. Pembrolizumab turned Merck from a diversified, mature pharmaceutical company into an oncology growth company. Each successful clinical trial increased more than the revenue of one indication. It expanded the drug’s physician familiarity, payer acceptance, safety database and usefulness as a combination backbone. That created a compounding regulatory moat: competing PD-1 drugs could be scientifically credible yet still lack the same breadth of labels and trial infrastructure. KEYTRUDA generated nearly $30 billion of revenue in 2024 and continued to expand in perioperative and adjuvant settings, where treatment occurs earlier in disease and eligible populations can be larger.

The market’s interpretation changed accordingly. Merck was no longer priced as a collection of mature primary-care drugs. It was awarded a growth and defensive-oncology identity, supported by earnings growth, clinical wins and the unusually long runway created by successive indication expansions. The share price’s strong 2019–2024 period reflected both rising KEYTRUDA earnings and greater confidence that new uses would extend growth toward the patent date. The market underappreciated the scale of KEYTRUDA early in that process; later it arguably underappreciated how difficult replacing such concentrated profit would be.

The fifth stage opened around Robert Davis’s 2021 elevation to chief executive and the Organon separation. Davis had joined as CFO in 2014, became president in April 2021, CEO in July 2021 and chairman in December 2022. The strategic aim became explicit portfolio reconstruction. Merck divested slower-growth women’s health and established brands through Organon, acquired Acceleron for WINREVAIR, bought Prometheus for tulisokibart, acquired Verona for OHTUVAYRE, and then committed approximately $16 billion to Cidara and Terns. Davis’s financial background is visible in the portfolio logic: concentrate capital on patent-protected, specialist products with substantial commercial potential. The risk is equally visible: the approaching cliff can turn disciplined urgency into price-insensitive urgency.

Several nodes still shape the current equity story. The Schering-Plough merger gave Merck global specialty scale. KEYTRUDA’s 2014 launch rebuilt growth and market confidence, and the 2021 Acceleron acquisition supplied WINREVAIR, now the clearest proof that external business development can create a new franchise. Prometheus, acquired in 2023, placed a large bet on TL1A biology and tulisokibart; Verona, acquired in 2025, added a commercial-stage respiratory drug rather than another distant pipeline option. The 2025–2026 QLEX launch provided the primary mechanism for retaining part of the KEYTRUDA base. Cidara and Terns then raised the capital-allocation stakes by putting large sums into one Phase III antiviral and one comparatively early hematology asset.

Merck’s selected financial history shows why investors tolerated concentration for so long.

Figures are rounded from Merck disclosures and financial-statement databases; 2025 Pharmaceutical revenue was $58.1 billion and Animal Health revenue was $6.4 billion.

Revenue has grown by product mix rather than unit volume across the whole company. KEYTRUDA’s indication expansion, price and treatment duration supplied most of the increase. Acquisitions contributed more recently through WINREVAIR and OHTUVAYRE, while Animal Health added steadier demand and pricing. Mature products moved in the opposite direction: Januvia/Janumet revenue fell 31% in Q2 2026, Dificid declined sharply after generic entry, Bridion reached U.S. loss of exclusivity in July 2026 and LAGEVRIO continued to contract with COVID demand. This is the normal pharmaceutical replacement treadmill made unusually visible by one enormous product.

Margins require two readings. On a reported basis, Q1 2026 gross margin fell to 74.2% from 78.0%, and Q2 gross margin fell to 73.5% from 77.5%, mainly because of acquired-intangible amortization, acquisition inventory adjustments, restructuring and write-downs. Q2 non-GAAP gross margin was about 81.1%, close to management’s approximately 81% full-year expectation. The underlying product economics remain attractive, but Merck’s adjusted margin increasingly excludes costs created by its acquisition strategy. Investors should therefore use adjusted margins to compare operating periods and full cash outlays to assess capital allocation.

Earnings and operating cash flow align over long periods better than the 2023 and 2026 income statements suggest. My reconstruction of 2021–2025 annual cash-flow statements gives cumulative operating cash flow of roughly $84 billion against cumulative net income of approximately $63 billion, an operating-cash-flow/net-income ratio near 1.3 times. The ratio is flattered by the fact that acquired in-process R&D charges reduce accounting income immediately while the cash purchase appears in investing activities. In 2025, Merck generated approximately $16.5 billion of operating cash flow and $12.36 billion of free cash flow after about $4.11 billion of capital expenditure.

Capital expenditure has risen as Merck adds biologics, vaccines and U.S. manufacturing capacity. The company does not disclose a clean maintenance-versus-growth split. I estimate maintenance capital expenditure at 55–65% of the 2025 total, or about $2.3–2.7 billion, based on the size of the existing production network and the visible expansion projects. The remainder supports new-product capacity and network expansion. This estimate is uncertain and is treated conservatively in the valuation.

The balance sheet was sound before the recent acquisition sequence, but it is less flexible now. At March 31, 2026, cash and investments were $6.8 billion, down from $15.5 billion at year-end after closing Cidara. Merck then arranged a $6 billion delayed-draw term loan to help fund Terns. Total debt was about $49–51 billion around the period, while the Verona, Cidara and Terns transactions together represented roughly $26 billion of announced consideration. The company can service that burden from operating cash flow; the issue is reduced freedom to correct further pipeline gaps without increasing leverage or sacrificing buybacks.

Shareholder distributions have remained substantial. Merck paid about $2.1 billion of dividends and repurchased approximately $874 million of shares in Q1 2026, at an average price around $114.07. Management had expected roughly $3 billion of 2026 repurchases before considering subsequent capital needs. The quarterly dividend was $0.85, implying $3.40 annually and a yield of about 2.66% at $128. Capital returned through dividends is well covered by normalized earnings, but the combination of dividends, repurchases and acquisitions has recently exceeded internally generated free cash flow.

Returns on invested capital appear excellent if the acquired R&D charges are ignored and weaker if purchase prices are fully capitalized. That is the correct economic tension. Internally discovered KEYTRUDA has generated extraordinary returns on decades of research infrastructure. Acquired programs must clear their purchase prices as well as ongoing development costs. WINREVAIR appears on track to earn an attractive return on Acceleron. Cidara and Terns will not be judgeable for years.

The price history of the last decade contains four main regimes. From 2016 to 2018, Merck traded as a defensive pharmaceutical company with an emerging oncology asset. KEYTRUDA’s success then drove earnings growth and multiple expansion from 2019 through 2022. Between 2023 and 2024, investors began balancing further oncology growth against a more visible 2028 expiry. In 2025, weak Gardasil demand in China, cautious guidance and the replacement gap pushed the shares to a 52-week low near $77.58. The subsequent rally toward $128 reflected QLEX approval, stronger clinical news, launch performance and renewed confidence that post-cliff revenue need not collapse permanently.

Current valuation comparisons must strip out the 2026 asset-purchase charges. The quoted trailing P/E around 36 times is high relative to mature pharma but economically misleading. The approximately 14.6-times charge-adjusted 2026 operational proxy is below the multiple generally paid for diversified growth peers such as AbbVie and AstraZeneca. The discount is rational because those companies have already reduced, or never had, Merck’s degree of single-product dependence.

Business Model, Moat, Industry, and Horizontal Competition

Merck reports two principal commercial businesses: Pharmaceutical and Animal Health. Pharmaceutical generated $14.76 billion of Q2 2026 revenue, or nearly 89% of consolidated sales. Animal Health generated approximately $1.78 billion, with companion-animal revenue of $734 million and BRAVECTO sales of $359 million. Other revenue was immaterial. Pharmaceutical growth came from oncology, cardiometabolic and respiratory products; diabetes and several mature medicines declined.

Within pharmaceuticals, oncology is the profit engine. KEYTRUDA and QLEX alone contributed $8.366 billion in the quarter. WELIREG, Lynparza alliance economics and newer oncology programs broaden the franchise, but none approaches KEYTRUDA’s scale. WINREVAIR produced $588 million, implying an annualized run rate above $2.3 billion. Vaccines remain strategically important, though Gardasil’s China disruption showed how distributor inventory, national procurement and local competition can overwhelm global epidemiological demand.

Animal Health is the stabilizer rather than the valuation center. It has less binary patent risk, a broad product set across livestock and companion animals, and exposure to pet spending, protein consumption, veterinary visits and agricultural disease control. Revenue grew 8% in Q2 2026 and 8% in full-year 2025. Its roughly $7 billion annualized scale could command a substantial standalone value, but its earnings cannot offset a rapid multibillion-dollar oncology decline.

The cost structure has high fixed and quasi-fixed components. Discovery research, global clinical trials, regulatory staff, biologics facilities, pharmacovigilance and commercial infrastructure cannot be reduced in line with one quarter’s sales. Manufacturing cost per dose is often small relative to branded price, giving successful products high incremental margins. That creates strong operating leverage during an indication-expansion cycle and adverse leverage after exclusivity loss. Merck’s $3 billion cost-savings program targeted for the end of 2027 can protect part of earnings, but cutting too deeply into research or launch capacity would weaken the replacement strategy.

Research spending is both a cost and the inventory-generation process of a pharmaceutical company. Merck Research Laboratories incurred approximately $2.5 billion of direct human-health research expense in Q1 2026 before the Cidara charge, while total reported R&D reached $12.6 billion after the $9 billion asset-acquisition expense. Q2 reported R&D was $9.7 billion, including $5.7 billion for Terns. The scale makes quarter-to-quarter R&D ratios almost meaningless unless business-development charges are separated.

Merck’s strongest moat is the clinical and regulatory network around KEYTRUDA. An oncology drug’s value depends on more than its molecular mechanism: approved tumor types, treatment lines, companion diagnostics, survival data, physician experience, guideline placement, manufacturing reliability and compatibility with other therapies all feed into it. Merck’s 17 ongoing Phase III sac-TMT studies and extensive KEYTRUDA combination programs illustrate how one established backbone lowers the commercial and clinical friction of testing the next asset. The moat remains economically powerful before expiry and can help launch combinations after expiry, but the molecule’s price protection will weaken.

Scale in development and commercialization is the second moat. Merck can run many multinational trials, negotiate with regulators, produce biologics and deploy specialized sales teams across oncology, cardiopulmonary medicine, vaccines and infectious disease. The LIPFENDRA program translated an oral macrocyclic PCSK9 inhibitor into the first approved once-daily oral drug in its class. WINREVAIR’s launch turned a specialist pulmonary-vascular asset into a $588 million quarter. These are observable capabilities rather than brand claims.

The third moat is therapeutic trust in vaccines and oncology. Physicians and health systems place high value on safety databases, supply reliability and real-world familiarity. That trust does not prevent competition: Vaxneuvance has lost demand to rival pneumococcal vaccines, Gardasil faced weaker Chinese demand and local alternatives, and Opdivo and Tecentriq compete in immuno-oncology. Trust improves adoption when clinical data support the product; it cannot rescue a drug with inferior efficacy, an inconvenient label or poor payer economics.

Fourth is financial capacity. Merck can spend $16 billion on Cidara and Terns, fund 17 Phase III ADC studies and absorb failed trials without threatening its survival. This capital advantage is real, but it becomes a disadvantage when urgency weakens price discipline. Large balance sheets do not improve clinical probabilities.

Customer switching costs vary by product. An individual patient responding to KEYTRUDA may remain on the drug through a treatment course, but new patients can begin a biosimilar or competitor once guidelines, payer policies and hospital formularies permit. Vaccines depend on public-health schedules and procurement decisions. Animal-health products benefit from veterinary familiarity and farm protocols, though switching remains possible. The moat is therefore strongest in evidence and channel position, less absolute in contractual lock-in.

Management’s record is mixed but above average. Robert Davis inherited the need to replace KEYTRUDA and moved earlier than many patent-cliff management teams. Acceleron and Verona brought assets with visible commercial paths. Prometheus gave Merck a potentially important immunology platform. The company also reorganized Human Health into dedicated oncology and specialty/infectious-disease units, aligning accountability with the bridge it must build.

The less favorable reading is that the prices and clinical stages have become more aggressive. Cidara cost approximately $9.2 billion for a portfolio whose value is dominated by MK-1406, a Phase III influenza-prevention candidate. Terns cost approximately $6.8 billion for a company whose main asset was in Phase I/II. Assuming a 60% probability of approval for MK-1406, a 55% probability of commercial success after approval and an acceptable return on development and financing, Cidara likely needs multibillion-dollar peak sales. Terns requires similarly large economics despite earlier-stage uncertainty. These are scenario inferences rather than company forecasts.

Governance is conventional for a large U.S. public company: no controlling founder, no dual-class structure and broad institutional ownership. The main alignment issue is compensation’s reliance on non-GAAP measures that exclude certain acquisition-related costs, while the company acknowledges that excluded items should not necessarily be considered non-recurring. The board should evaluate scientific business development on full returns to capital, not only the post-charge earnings trajectory.

The pharmaceutical industry is mature in volume but grows through innovation and mix. IQVIA expects global medicine spending to continue rising through 2030, driven heavily by novel drugs in developed markets, while underlying medicine-use growth is much slower. Oncology remained the largest prescription category, with approximately $288 billion of 2025 sales according to IQVIA. The industry profit pool resides in differentiated, patent-protected therapies with strong clinical benefit; generic manufacturing, commodity distribution and undifferentiated primary-care products retain much less of the economics.

Merck is economically defensive but technologically cyclical. Demand for cancer care, vaccines and livestock medicines does not track GDP closely. The internal cycle is the patent and product cycle: discovery, trials, approval, launch, indication expansion, maturity and abrupt loss of exclusivity. Interest rates matter to valuation and acquisition financing, while policy determines pricing and the speed with which competitors can enter.

Payers have increasing bargaining power. U.S. Medicare negotiation, inflation penalties, Part D redesign and international reference-pricing systems reduce manufacturers’ ability to convert every clinical advance into unconstrained price. Merck’s filings identify government cost-containment measures as a central risk. Januvia has already entered Medicare negotiation processes, and the company has warned of pricing pressure on major products. The exact timing of negotiated effects can change with legislation and litigation, but the direction is toward more payer intervention.

Regulators also influence the cliff through biosimilar rules. The FDA’s effort to simplify portions of biosimilar development can lower development costs and encourage more entrants. More than one pembrolizumab biosimilar sponsor is already in advanced studies. A crowded launch cohort would intensify net-price erosion even if Merck defends secondary patents into 2029.

Geopolitical risk is meaningful but secondary to product risk. Merck manufactures and sells globally, faces foreign-exchange swings and depends on multinational clinical and supply networks. China has become a larger source of drug development and an important commercial market, but Gardasil’s experience shows the limits of assuming that population need translates smoothly into revenue. U.S.-China policy can affect licensing, trials, data, manufacturing partners and investor perceptions, while pharmaceutical tariffs could raise cost and encourage redundant manufacturing capacity.

The most useful horizontal peer set is Bristol Myers Squibb, AbbVie, AstraZeneca and Novartis. Bristol Myers is the closest valuation analogue for a company facing major expiries. AbbVie is the most relevant transition precedent because it successfully replaced a large portion of Humira’s lost earnings with Skyrizi and Rinvoq. AstraZeneca is the oncology-growth benchmark, Novartis the focused, diversified innovative-medicines benchmark.

Market capitalizations and prices come from U.S.-listed quotes; earnings multiples use company guidance or contemporary market estimates and are not perfectly accounting-comparable.

Bristol Myers became the market’s “show me” pharmaceutical company. Its growth portfolio was expanding 15% in Q2 2026, but investors assigned a sub-10-times adjusted-earnings multiple because several established products face erosion and debt remains meaningful. Its lesson for Merck is that apparent cheapness can persist through a cliff; the market waits for replacement products to exceed declining revenue, not merely to grow quickly from small bases.

AbbVie is the reference case for a successful cliff transition. Humira sales declined sharply after biosimilars, but Skyrizi and Rinvoq grew rapidly enough to restore corporate growth. Customers choose those products because they produced compelling efficacy in large immunology markets, while AbbVie invested heavily in indication expansion before Humira’s U.S. expiry. AbbVie’s higher multiple reflects evidence that the replacement engines are already commercial. Merck has WINREVAIR and QLEX evidence, but much of its bridge remains in development.

AstraZeneca compounds through a diversified oncology franchise. Its cancer portfolio spans targeted therapies, antibody-drug conjugates, immuno-oncology and rare disease without one product generating half of company revenue. Physicians choose AstraZeneca products for indication-specific data rather than a single universal platform. The market pays more for the breadth and duration of that growth, even though AstraZeneca also faces trial, pricing and execution risk.

After divesting consumer and generics interests, Novartis became a focused innovative-medicines company. Its valuation reflects a cleaner portfolio, disciplined capital allocation and less extreme product concentration. It lacks KEYTRUDA’s single-franchise upside but also has less exposure to one 2028 event.

Merck occupies the niche of incumbent oncology platform plus transition acquirer. It is stronger than Bristol Myers in current franchise momentum and weaker than AbbVie in demonstrated post-cliff replacement. It has a broader clinical platform than many peers, but less revenue diversification than AstraZeneca or Novartis. The company takes profit from oncology treatment budgets, specialist cardiovascular and respiratory markets, vaccines and animal health. Biosimilar manufacturers, competing oncology regimens, payer formularies and unsuccessful trial outcomes are the principal routes by which that profit pool can move elsewhere.

Current Fundamentals and Bull/Bear Divergence

The last four reported quarters show a business growing modestly beneath unusually noisy accounting.

Q3 2025 benefited from fewer business-development charges than the comparable period and delivered GAAP EPS of $2.32. Q4 revenue and adjusted EPS beat expectations, but the initial 2026 outlook disappointed because it incorporated the Cidara charge, modest revenue growth and continuing Gardasil pressure. Q1 2026 then beat reduced earnings expectations despite the Cidara charge. Q2 again exceeded revenue and adjusted-loss expectations. The sequence suggests that underlying operations are outperforming the cautious expectations formed after the 2025 selloff.

QLEX is the most important current operating metric. Sales rose from $128 million in Q1 to $463 million in Q2. The sequential increase was partly launch progression rather than a repeatable growth rate, but it shows that clinics and patients value a one-to-two-minute subcutaneous administration compared with an intravenous infusion of roughly 30 minutes. The product’s early penetration has reached a double-digit share of U.S. KEYTRUDA sales according to Reuters. A move toward management’s 30–40% target would retain a meaningful franchise after intravenous competition, while a plateau below 20% would remove much of the bull argument.

WINREVAIR is the strongest non-KEYTRUDA growth asset. Quarterly revenue progressed to $588 million, up 75%, after $525 million in Q1. Pulmonary arterial hypertension is a specialist market with substantial unmet need, and sotatercept’s differentiated mechanism has supported rapid adoption. The risks are physician sequencing, long-term safety, competition and the finite prevalent-patient pool. Even so, a $3–5 billion franchise appears more plausible now than it did at launch.

WELIREG is developing into a useful oncology asset, with Q2 sales around $271 million and strong year-on-year growth. Expanded combination use with KEYTRUDA in renal-cell carcinoma can increase its commercial reach and reinforce Merck’s oncology channel. CAPVAXIVE, ENFLONSIA, OHTUVAYRE and IDVYNSO provide additional launches, but their collective size matters more than any one quarter’s percentage growth.

LIPFENDRA is strategically important because an oral PCSK9 inhibitor can reach patients who resist injections and can use Merck’s cardiometabolic commercialization experience. Merck reported LDL cholesterol reductions around the high-50% range in pivotal studies, competitive with injectable biology on a mechanistically different platform. Commercial value will depend on payer access, real-world adherence, price and whether clinicians use it before or after lower-cost statins and ezetimibe. FDA approval de-risked the asset technically; reimbursement and launch execution remain unresolved.

Sac-TMT moved from an attractive platform to a partially validated late-stage program when TroFuse-005 met overall-survival and progression-free-survival endpoints in advanced or recurrent endometrial cancer. Merck and Kelun are running 17 global Phase III studies across tumors. The program can become a major post-KEYTRUDA franchise if efficacy, toxicity and manufacturing support multiple approvals. ADC competition is intense, and one positive trial does not prove success in lung, breast or other larger markets.

Tulisokibart produced the kind of mixed evidence expected from a broad immunology program. It met primary and key secondary endpoints in Phase III ulcerative-colitis induction and generated positive Phase II hidradenitis-suppurativa data, while another pulmonary indication failed. The positive results strengthen the Prometheus acquisition thesis, but durable remission, maintenance data, safety and differentiation against established biologics and oral agents will determine commercial value.

The once-weekly oral islatravir/lenacapavir combination maintained virologic suppression in Phase III and could become the first approved weekly oral HIV treatment. Convenience is commercially meaningful in a chronic disease, but the collaboration with Gilead divides economics and the earlier islatravir lymphocyte-safety issue remains part of the program’s history. Regulatory review and prescriber confidence matter more than the novelty of weekly dosing alone.

The market is currently trading four fundamental developments rather than a temporary theme: QLEX conversion, evidence that new launches can exceed $1 billion quickly, a denser set of positive late-stage readouts, and higher confidence in 2026 revenue. It is also trading a capital-market narrative that Merck can repeat AbbVie’s successful transition. The latter has moved faster than the evidence. AbbVie entered Humira’s cliff with two commercial replacement franchises already generating many billions of dollars. Merck still depends on several assets crossing clinical, regulatory and reimbursement hurdles between now and 2030.

The strongest bull case starts with franchise retention. QLEX reached $463 million in its second full quarter, treatment time is materially shorter, and management’s 30–40% target would preserve a large share of patients from direct intravenous switching. Further perioperative KEYTRUDA approvals may support demand through 2028. Merck also has the financial and clinical capacity to defend patents and negotiate settlements.

A second bull argument says the replacement portfolio is already larger than the market credits. WINREVAIR’s $588 million quarter, LIPFENDRA approval, WELIREG growth, commercial OHTUVAYRE revenue, positive sac-TMT and tulisokibart data, and a weekly HIV regimen span several therapeutic areas. The portfolio does not require one drug to become another KEYTRUDA if five to eight products each reach several billion dollars.

The third bull argument is valuation. At $128, the stock trades around 14.6 times the operational proxy obtained by adding the disclosed Cidara and Terns burdens to 2026 guidance. A diversified pharmaceutical company with high-single-digit normalized EPS growth would usually command more. If post-cliff revenue returns to growth by 2031, Merck could re-rate toward peer multiples while continuing to pay dividends.

The strongest bear case starts with concentration. The KEYTRUDA family generated just over half of Q2 sales and likely a still higher share of operating profit because of biologic gross margins and mature commercial infrastructure. Even 40% QLEX conversion leaves most current volume exposed. Samsung Bioepis, Celltrion, Amgen, Sandoz and others are not waiting for 2028 to begin development. Multiple entrants can compete on payer rebates before clinical practice changes organically.

The second bear argument is the amount Merck has paid for uncertain science. Cidara and Terns cost approximately $16 billion combined. Their accounting treatment makes 2026 EPS temporarily ugly but later adjusted figures clean; economic returns remain binary. If one fails and the other produces only a niche product, billions of dollars of shareholder capital will have earned little while leverage and interest costs increased.

A third bear point is that launch arithmetic is routinely misleading. Ten drugs with $1 billion in sales do not replace $10 billion of KEYTRUDA profit if they carry royalties, acquired-intangible amortization, expensive specialist salesforces and lower margins. Merck’s non-GAAP gross-margin guidance has already moved from approximately 82% to 81%, while SG&A is rising to support launches.

The fourth bear argument is that a large portion of the 2026 rally reflects future success before the decisive evidence arrives. The shares moved from below $80 to $128, while the most important post-cliff assets still need maintenance data, regulatory reviews, broader pivotal wins and commercial reimbursement. The market may be pricing the probability-weighted pipeline more generously than it priced it in 2025, but the underlying scientific probabilities did not rise by 60% across every program.

Valuation, Cash-Flow Passthrough, and Expectation Gap

The owner-earnings analysis starts with cash conversion. Merck generated about $12.36 billion of reported 2025 free cash flow after $4.11 billion of capital expenditure. That equates to roughly $5.00 per diluted share and a headline FCF yield near 3.9% at $128, materially below the yield suggested by adjusted EPS. The gap partly reflects working-capital timing, restructuring, acquisition integration, tax and growth capital expenditure. A single year understates normalized cash earning power, while simply using adjusted EPS overstates it by ignoring full acquisition economics.

Across 2021–2025, cumulative operating cash flow was about 1.3 times cumulative net income, but the ratio is distorted upward by acquired R&D charges recorded through income while acquisition payments are classified as investing cash outflows. My normalized owner-earnings range for 2026 is $8.00–8.70 per share after estimated maintenance capital expenditure, recurring cash taxes and interest, but before treating new acquisitions as recurring annual capex. At $128, this implies a normalized owner-earnings multiple of roughly 14.7–16.0 times and an owner-earnings yield of 6.3–6.8%.

Maintenance capital expenditure is not disclosed. The model assumes $2.5 billion in 2026 dollars, around 60% of recent total capital expenditure, and regards the balance as growth and network-expansion spending. Raising maintenance capital expenditure by $1 billion reduces value by roughly $4–6 per share, depending on the scenario multiple.

Historical valuation offers limited comfort. Merck’s trailing P/E has ranged from apparently low levels during clean high-earnings periods to extremely high or meaningless levels after acquired-R&D charges. The relevant comparison is normalized pre-cliff earnings. At 14–16 times owner earnings, the stock is below diversified growth-pharma peers but above the distressed-cliff valuation applied to Bristol Myers. That position is appropriate: Merck has better current growth and pipeline momentum than Bristol Myers, but less replacement proof than AbbVie and more concentration than AstraZeneca.

The absolute valuation explicitly models the cliff rather than hiding it in a terminal-growth rate. Q2 annualized KEYTRUDA-family revenue is about $33.5 billion. The scenarios assume the franchise peaks around 2027–2028, after which intravenous erosion and QLEX retention diverge.

†Contribution is incremental sales from major launches, acquired assets and late-stage pipeline beyond the mature ex-KEYTRUDA base; it does not include every existing product.

The conservative case assumes aggressive biosimilar entry, a QLEX plateau around 20%, limited success from Cidara and Terns and only partial contribution from the late-stage portfolio. It does not assume corporate collapse. Merck retains Animal Health, vaccines, mature pharmaceuticals, WELIREG, WINREVAIR and some KEYTRUDA economics. The $110 present value includes substantial pre-cliff cash flow but values the post-cliff company at a mature multiple.

The base case assumes QLEX reaches management’s 30–40% ambition, intravenous erosion resembles a competitive biologic cliff rather than an instant generic collapse, and WINREVAIR, LIPFENDRA, OHTUVAYRE, WELIREG, sac-TMT, tulisokibart and other products collectively contribute $15–18 billion of 2031 sales above the mature base. It assumes neither Cidara nor Terns must become a $10 billion product. Value is about $130, close to the current quote.

The optimistic case requires several things to work at once. QLEX must reach roughly half of eligible patients, Merck must delay or soften intravenous entry through patents and settlements, and the pipeline must produce multiple large franchises. Sac-TMT succeeds across more than one major tumor, tulisokibart becomes a competitive immunology product, LIPFENDRA gains broad reimbursement, and at least one of MK-1406 or MK-4208 earns a strong return. The resulting $158 value is plausible but cannot serve as the purchase base.

This is valuation-scenario analysis within a research framework, not investment advice.

The market at $128 appears to price a result close to the base case: a meaningful but manageable 2029–2030 earnings decline, QLEX conversion near the lower end of management’s target, and enough pipeline success to restore growth around 2031. It does not price an immediate KEYTRUDA collapse. It also does not price the full optimistic portfolio.

The next expectation gaps will be created by QLEX sales and share, not headline KEYTRUDA growth alone; the breadth of sac-TMT success; tulisokibart maintenance data; LIPFENDRA formulary access; WINREVAIR’s new-patient trajectory; and management’s peak-sales disclosures. The October 26, 2026 oncology investor event will be particularly important for sac-TMT, oncology combinations and the post-KEYTRUDA architecture. Merck’s next quarterly report is scheduled for October 29, 2026.

The margin-of-safety recheck is less favorable than the headline normalized multiple. The current price is 16% above the $110 conservative value, so the margin of safety against that case is zero. The most fragile base assumption is the $15–18 billion replacement contribution in 2031. Reducing that contribution to 70% lowers my base valuation from $130 to approximately $118 per share.

If normalized owner earnings remain flat for three years and the valuation multiple is unchanged, the primary return would be the approximately 2.7% dividend yield, perhaps 2.5–3.0% annually after modest dividend growth and reinvestment effects. That is below the 4.63% 10-year U.S. Treasury yield recorded for August 4, 2026. There is no margin of safety at this buy price under the flat-earnings test.

Merck is a good company at a price that already reflects a workable bridge. Waiting for a better price is economically rational unless new evidence raises conservative value. The margin-of-safety sufficiency verdict is: none.

Risk Analysis, Catalysts, and Tracking Indicators

The highest-probability, highest-impact risk is KEYTRUDA erosion that outruns the replacement portfolio. The observable indicators are QLEX conversion, tender and formulary decisions, biosimilar trial completions, patent litigation and net price. The transmission path is direct: lower KEYTRUDA volume and price reduce gross profit faster than research and manufacturing costs can fall, followed by an earnings multiple reduction if investors conclude that the bridge failed. With multiple biosimilar developers already active and FDA policy moving toward simpler development, the probability of material erosion is high; the uncertainty concerns timing and magnitude.

Pipeline and acquisition failure is the second risk, medium in probability and high in impact. Cidara and Terns represent approximately $16 billion of capital for assets that still face clinical, regulatory and commercial risk. Observable indicators include MK-1406 Phase III efficacy and safety, regulatory interactions, MK-4208 response durability and competitor data in influenza prophylaxis and chronic myeloid leukemia. Failure would reduce expected pipeline value, raise questions about management’s discipline and make further acquisitions more expensive because the company would still need replacement revenue.

A third risk is that successful products produce less cash than headline sales imply, a medium-probability outcome with medium-to-high impact. Many replacement products involve royalties, profit sharing, acquired-intangible amortization or specialized launch spending. Non-GAAP gross margin has already eased toward 81%, while SG&A rose 10% in Q2 to support launches and administration. If revenue grows while owner earnings stagnate, the market could abandon normalized EPS and value Merck on free cash flow.

Capital-structure compression comes fourth, medium in both probability and impact. Cash and investments fell to $6.8 billion at March 31 after Cidara, and Terns was supported by a $6 billion facility. Higher interest expense was already visible in Q2. Merck has ample operating liquidity, but another $10 billion acquisition could push net debt toward a level that constrains buybacks, dividend growth or development spending. The relevant indicator is net debt divided by normalized owner earnings, not reported EPS during acquisition-charge quarters.

The fifth risk, policy-driven pricing compression, is high in probability and medium in impact. U.S. government negotiation and inflation penalties, international tendering and potential changes to biologics reimbursement can reduce net price before physical biosimilar entry. A policy that accelerates interchangeable substitution or makes infused biosimilars financially more attractive to providers would weaken QLEX conversion economics. The indicators are CMS pricing publications, Part B reimbursement rules and Merck’s U.S. price/mix commentary.

Gardasil and vaccine volatility are a sixth, smaller risk. The probability of continued quarterly volatility is high, but its long-run impact is medium. China distributor inventory, local vaccine competition, purchasing policies and vaccination guidance caused major swings despite substantial underlying medical need. That recovery has in fact begun: Gardasil/Gardasil 9 sales were $1,169 million in the second quarter of 2026, up 4%, on higher demand in Asia Pacific and Europe. A structural share loss would still reduce one of the few large non-oncology franchises.

Litigation exists but is not the core valuation risk. Merck has faced Gardasil product claims, securities litigation linked to Chinese demand disclosures, antitrust matters and government inquiries. Based on current public disclosures, no single proceeding appears comparable in expected value to the patent-cliff risk. A material adverse judgment could still affect cash and reputation, so legal accruals and case progress warrant monitoring.

Positive catalysts over the next 12 months include QLEX exceeding the 30–40% adoption path, continued WINREVAIR prescription growth, strong LIPFENDRA formulary coverage, regulatory filings for sac-TMT, favorable tulisokibart maintenance data, additional KEYTRUDA perioperative approvals, and evidence that OHTUVAYRE can expand internationally. A disciplined pause in large acquisitions would also improve confidence in balance-sheet management.

Negative catalysts include a QLEX sales plateau, an early settlement permitting several intravenous biosimilars soon after December 2028, an unexpected safety issue in WINREVAIR or tulisokibart, weak LIPFENDRA reimbursement, failed sac-TMT trials outside endometrial cancer, or another large early-stage acquisition financed with debt.

‡Indicative basket including WINREVAIR, WELIREG, OHTUVAYRE, CAPVAXIVE, QLEX incremental sales and other major launches; definitions should be kept consistent from quarter to quarter.

QLEX should be tracked through both dollars and conversion. Revenue can rise because total KEYTRUDA volume rises even if conversion disappoints. U.S. patient or dose share is the cleaner lifecycle measure. Merck’s filings, earnings materials and oncology events are the primary sources.

Replacement-product sales should be combined because the cliff will be bridged by a portfolio. Investors can create a consistent quarterly basket and compare its absolute dollar increase with the eventual absolute KEYTRUDA decline. Percentage growth from small bases will otherwise exaggerate progress.

Cash metrics require adjustment for acquired-R&D payments. Net debt should be compared with normalized owner earnings, while acquisition purchase prices should be separately accumulated and evaluated against eventual product cash flows. Treating the purchase price as irrelevant after the initial EPS charge would overstate returns.

Cross-Synthesis, Final Conclusion, Key Data, Uncertainties, and Sources

Looking vertically, Merck has proven one capability across more than a century: it can build durable institutional machinery around biomedical innovation. The company began as a distributor, built a research laboratory, expanded into vaccines and chronic medicines, used a transformational merger to increase global specialty scale and then converted pembrolizumab into the broadest oncology commercial platform of its era. KEYTRUDA’s success included scientific insight, clinical execution, regulatory speed, manufacturing reliability and persistent indication expansion. It was not simply an era tailwind. Other large pharmaceutical companies had access to immuno-oncology science; Merck created more value from it than most.

Luck still played a role. Drug discovery is probabilistic, and KEYTRUDA’s eventual breadth could not have been known when the asset entered development. Favorable oncology biology, rising global cancer spending and payer willingness to fund meaningful survival benefits amplified the outcome. Management capability turned that favorable biology into a franchise; it did not create the biology itself.

Those capabilities remain present. The TroFuse program, LIPFENDRA approval, WINREVAIR launch and tulisokibart development show that Merck can still run large trials and commercialize specialist medicines. The balance sheet, oncology relationships and regulatory infrastructure remain advantages. The expiring asset is the patent-protected molecule, not the organization.

The weakness is structural concentration. Q2 sales show that every dollar of company revenue still contains roughly 50 cents of KEYTRUDA-family revenue. Profit concentration is probably greater. A company can retain scientific quality while its stock produces poor returns if the market overvalues the replacement rate. Merck must create several successful franchises merely to keep owner earnings stable around 2030.

Horizontally, Merck’s advantage over Bristol Myers is stronger current oncology momentum and a more visible launch portfolio. Its weakness relative to AbbVie is that the replacement transition has not yet been commercially proven. Its weakness relative to AstraZeneca and Novartis is concentration. Its distinct advantage is that KEYTRUDA itself can help launch combinations and adjacent oncology assets during the remaining exclusivity period.

The stock price rewards part of this future success in advance. The normalized 14–16-times owner-earnings multiple appears modest when viewed against 2026 earnings, but those earnings are near the top of a patent cycle. A declining asset should not be valued solely on current yield. At $128, the market is implicitly paying for QLEX to retain a meaningful share, for WINREVAIR and other launches to continue scaling, and for several pipeline programs to succeed.

The market’s most likely misjudgment is more subtle than “the cliff is ignored” or “the cliff is fully priced.” Investors may be underestimating the value of Merck’s broad launch system while overestimating how much of each new product’s revenue reaches owners. The replacement portfolio can produce substantial sales and still leave earnings below the KEYTRUDA peak because acquired products carry purchase prices, royalties, financing costs and launch expense.

For the next year, the critical variables are QLEX conversion, WINREVAIR growth, LIPFENDRA access, sac-TMT filing plans and 2027 guidance. Over three years, the critical variables become the timing of biosimilar launches, KEYTRUDA net price, tulisokibart and sac-TMT approvals, and cumulative replacement-product sales entering 2029. Over five years, value will be determined by whether owner earnings bottom above roughly $6–7 per share and return to growth, or fall toward $4–5 while debt remains elevated.

Merck becomes a better investment under either of two conditions. The first is price: a decline into the $82 to $88 zone would offer at least a 20% discount to the conservative value. The second is evidence: QLEX conversion above 40%, replacement products approaching a $15 billion annualized run rate by 2028 and multiple successful late-stage programs would raise conservative value even if the share price did not fall.

The judgment should be reconsidered negatively if QLEX remains below 20% of U.S. KEYTRUDA use by mid-2027, if two major sac-TMT trials fail, if tulisokibart maintenance results are weak, if management adds another debt-funded early-stage acquisition above $10 billion, or if biosimilar settlements permit several entrants earlier than assumed. It should be reconsidered positively if QLEX reaches 40–50%, LIPFENDRA secures broad access, WINREVAIR exceeds a $4 billion annualized trajectory and one of MK-1406 or MK-4208 becomes substantially de-risked.

Bull reasons:

• QLEX generated $463 million in Q2 2026 after $128 million in Q1, providing early evidence that a material portion of patients may convert before intravenous biosimilars arrive.
• WINREVAIR reached $588 million of quarterly sales, validating at least one major post-2021 acquisition and establishing a likely multibillion-dollar franchise.
• LIPFENDRA approval and positive Phase III results for sac-TMT, tulisokibart and weekly islatravir/lenacapavir broaden the replacement portfolio across several therapeutic areas.
• At $128, Merck trades at roughly 14.6 times the operational 2026 EPS proxy after adding back the separately disclosed Cidara and Terns burdens.
• Merck’s oncology data network and global development infrastructure increase the probability that successful pipeline assets can be launched at scale.

Bear reasons:

• KEYTRUDA and QLEX produced 50.4% of Q2 revenue, leaving the company more concentrated than major diversified-pharma peers as multiple biosimilars advance.
• Even management’s 30–40% QLEX adoption ambition leaves most current use exposed, and the public FDA record does not verify blanket exclusivity through 2039.
• Cidara and Terns consumed about $16 billion for assets that still face substantial clinical and commercial risk.
• Current price is 16% above the conservative value and the dividend yield is below the 10-year Treasury yield.
• The 2026 rally from the high-$70s to $128 has capitalized several pipeline successes before pivotal breadth, reimbursement and post-cliff margins are known.

A first pre-mortem script begins in 2028. Samsung Bioepis’s SB27, Amgen’s ABP 234 and other pembrolizumab biosimilars obtain approvals or settlement-defined launch dates. By 2029, two or more products enter at net prices 35–45% below intravenous KEYTRUDA. QLEX conversion stalls near 20% because payers favor lower-cost infusions. Intravenous volume declines 65% in the first full year, corporate gross margin falls below 76%, and normalized EPS drops toward $5.50. Investors apply an 11-times multiple to a company still searching for growth, producing a share price around $60 before dividends, roughly 53% below the research-date price.

A second script begins with pipeline disappointment. Sac-TMT succeeds only in the initial endometrial indication but fails in two large lung and breast trials; tulisokibart’s maintenance efficacy is undifferentiated; MK-1406 fails to show commercially persuasive benefit in Phase III; and MK-4208 remains a niche later-line leukemia product. Merck records impairments, continues spending heavily on business development and reaches 2030 with normalized EPS around $5 while net debt remains elevated. A 12-times multiple again implies about $60. The loss path combines lower earnings and lower confidence rather than one catastrophic event.

Merck remains a scientifically capable, cash-generative company whose current asset concentration creates a finite strategic deadline. The Q2 2026 evidence is better than the evidence available in May: QLEX is converting patients quickly, WINREVAIR is scaling, revenue guidance rose and several pipeline programs cleared important hurdles. Those developments justify moving the research rating from Watch to Hold.

Ownership at $128 depends on accepting little immediate margin of safety. The current quote sits close to my $130 base value, above the $110 conservative value and below the $158 optimistic value. Existing shareholders can reasonably hold through upcoming data if position size reflects the cliff. New capital should demand either a lower price or stronger evidence that replacement-product cash flow, rather than revenue headlines, can rebuild the post-2028 earnings base.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: strong
• Financial soundness: medium
• Management credibility: high
• Valuation attractiveness: medium
• Risk level: high
• Suitable investor type: value and dividend investors able to underwrite clinical and patent-cliff risk; not suitable as a low-monitoring defensive holding

【Investment rating】

• Rating: Hold
• One-line thesis: QLEX and the new-product portfolio improve the bridge, but $128 already discounts a broadly successful post-2028 transition.
• Ideal buy price:

【Ideal Buy Price】82–88 USD

Basis: at least 20% below the $110 conservative scenario value, with the upper boundary equal to 80% of conservative value.

• Acceptable hold price: 112–148 USD, centered on the $130 base value and broadly within ±15%.
• Clearly overvalued price: 174 USD and above, at least 10% above the $158 optimistic value.
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A price of 88 USD or below is the preferred trigger without new evidence. A higher purchase price could be justified if QLEX conversion exceeds 40%, replacement products exceed a $15 billion annualized run rate before the cliff and at least two major pipeline franchises are substantially de-risked. The opportunity cost of waiting is the dividend and potential re-rating after positive clinical data.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative -2% to 0%; base 2–4%; optimistic 7–9%, including dividends and assuming convergence toward scenario values over approximately four years
• Max-loss risk: approximately 49–55%, with a $58–65 trough if aggressive biosimilar entry coincides with weak pipeline replacement and a multiple near 11–12 times depressed earnings
• Reassessment-trigger signals: QLEX conversion below 20% by mid-2027; two major sac-TMT Phase III failures; normalized gross margin below 79% for two quarters; net debt above three times owner earnings after another acquisition; replacement-product annualized revenue below $12 billion by end-2028

【Valuation Range】

• current: 128.00 (close as of 2026-08-04)
• bear (conservative · ideal buy zone): [82, 88]
• base (fair · acceptable hold zone): [112, 148]
• bull (optimistic · above the clearly-overvalued line): [174, 190]

Key data recap:

Research uncertainties:

First, no public source allows precise prediction of KEYTRUDA biosimilar launch dates. Patent litigation and settlements can change the commercial timeline abruptly. The scenarios therefore model erosion shapes rather than assert a specific first-launch date.

Second, the QLEX patent estate is complex. FDA approval and the Purple Book establish the licensed product, not the enforceability of every formulation, device, enzyme and manufacturing patent. The report assigns no blanket 2039 exclusivity.

Third, maintenance capital expenditure is not separately disclosed. The 55–65% estimate affects owner earnings and can be wrong by roughly $1 billion annually.

Fourth, Merck has not supplied directly comparable risk-adjusted net-present values for every acquired asset. Pipeline values use explicit scenario probabilities and commercial assumptions, not management peak-sales claims.

Fifth, the Q2 2026 report was published one day before the research date. Analyst models, target prices and consensus estimates had limited time to incorporate the quarter, so peer-forward estimates and expectation-gap observations may move after publication.

Primary research sources include Merck’s Q2 and Q1 2026 earnings releases, its Q1 2026 Form 10-Q, the 2025 full-year release, Merck’s investor-event calendar, FDA approval and Purple Book records, Merck’s official corporate history, SEC merger records, U.S. Treasury yield data, peer disclosures and contemporaneous Reuters, Wall Street Journal and Barron’s reporting.

Other tickers mentioned

• BMY.US: closest large-pharma comparison for a discounted company managing several major losses of exclusivity
• ABBV.US: primary precedent for replacing a dominant biologic franchise with successful new immunology products
• AZN.US: diversified oncology-growth benchmark with less dependence on one molecule
• NVS.US: focused innovative-medicines peer used for portfolio quality and valuation comparison
• JNJ.US: former immunology partner and a major diversified pharmaceutical competitor
• GILD.US: development partner for the once-weekly islatravir and lenacapavir HIV regimen
• MRNA.US: partner on the personalized cancer-vaccine program combined with KEYTRUDA
• AMGN.US: developer of a pembrolizumab biosimilar candidate and large-cap biotechnology peer
• HALO.US: intellectual-property counterparty in the subcutaneous-drug-delivery landscape
• ROG.SW: oncology competitor with established subcutaneous immunotherapy experience

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.